Schrödinger Beats on Revenue Growth, Raises Full-Year ACV and Drug Discovery Outlook
SDGR has more than doubled off its 52-week low of $10.945.
Summary
Schrödinger posted Q3 total revenue of $64.5 million, up 19%, with drug discovery revenue nearly doubling to $24.2 million from $13.0 million on a Structure Therapeutics milestone. ACV rose 17% to $44.7 million and hosted software revenue jumped 49%, showing the shift to hosted licenses is landing. The company raised FY2026 ACV guidance to $222-232 million (12-17% growth) from $218-228 million and drug discovery revenue to $75-85 million from $65-75 million, while keeping opex below 2025. The offset: net loss widened to $37.7 million from $32.8 million, or 50 cents a share, driven by an $11.4 million other-expense swing from mark-to-market on equity holdings, not operations. Cash and marketable securities stand at $373 million. Updated Phase 1 data for SGR-1505 is set for an oral session at ASH, December 12-15, 2026, though the company corrected its ASH abstract to note that no combination study of SGR-1505 has been initiated under its FDA-cleared protocol, and it is exploring strategic options for the program.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Schrödinger corrected its ASH abstract: no combination study of SGR-1505 has been initiated under its FDA-cleared protocol, and it is exploring strategic options for the program.
At the time of this announcement, SDGR was trading at $28.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.